References
- Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. Pain 1999; 82: 263–274.
- Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999; 353: 1695–1700.
- World Health Organization. Cancer pain relief: with a guide to opioid availability. 2nd ed. Geneva: World Health Organization. 1996.
- Moulin DE. Neuropathic cancer pain: syndromes and clinical controversies. In: Portenoy RK, Bruera E, eds. Topics in palliative care. Vol 2. New York: Oxford University Press, 1998: 7-29.
- Portenoy RK. Adjuvant analgesics in pain management. In: Doyle D, Hanks GW, MacDonald N, eds. Oxford textbook of palliative medicine. New York: Oxford University Press, 1998: 361–390.
- Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropa-thy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280: 1831–1836.
- Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280: 1837–1842.
- Allen RR. Neuropathic pain: mechanisms and clinical assessment. In: Payne R, Patt RB, Hill CS, eds. Assessment and treatment of cancer pain, Progress in Pain Research and Management. vol.12. Seattle: IASP Press, 1998: 159-173.
- Caraceni A, Zecca E, Cinzia M, De Conno F. Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. J Pain Symptom Mngmt 1999; 17: 441–445.
- Lossignol DA, Mancini I, Plehiers B, Obiols M, Body JJ. Successful treatment of neuropathic cancer pain with gabapentin. Support Care Cancer 2000; 8: 245.
- Simon R. Optimal two-stage designs for phase II trials. Contr Clin Trials 1989; 10: 1–10.
- Chapman RC, Syrjala KL. Measurement of pain. In: Bonica JJ, ed. The management of pain. 2nd edition. Philadelphia: Lea & Febinger, 1990: 580–594.
- Melzack R. The McGill Pain Questionnaire: major prop-erties and scoring methods. Pain 1975; 1: 277–299.
- Rosner H, Rubin L, Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states: case report. Clin J Pain 1996; 12: 56–58.
- Rosenberg JM, Harrell C, Ristic H, Werner RA, de Rosayro AM. The effect of gabapentin in neuropathic pain. Clin J Pain 1997; 13: 251–255.
- Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999; 353: 1959–1964.
- Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280: 1837–1842
- Wetherill GB, Glazebrook KD. Sequential methods in statistics. London, Chapman and Hall, 1986.
- Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999; 83: 389–400.